Home > Products > Montair
Share Print This Page

Montair (Montelukast)
Therapeutic Group: Respiratory » Anti Asthmatics » Leukotriene Receptor Antagonist

Montair 4 Chewable Tablet : Each tablet contains Montelukast Sodium INN equivalent to Montelukast 4 mg.

Montair 5 Chewable Tablet : Each tablet contains Montelukast Sodium INN equivalent to Montelukast 5 mg.

Montair 10 Tablet : Each tablet contains Montelukast Sodium INN equivalent to Montelukast 10 mg.

Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma ( such as, airway edema, smooth muscle contraction and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma).
Montelukast is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients from 6 months of age and older.
Dosage & Administration
Adults (15 years of age or over): 10 mg daily to be taken in the evening.
Children (6-14 years of age): 5 mg daily to be taken in the evening.
Children (6 months-5 years of age): 4 mg daily to be taken in the evening.
Safety and effectiveness of Montelukast in pediatric patients younger than two years of age have not been established.
The safety and efficacy of Montelukast was demonstrated in clinical trials where it was administered in the evening without regard to the time of food ingestion.
Side Effects
Generally, Montelukast is well-tolerated. Side effects include dizziness, headache, diarrhea, restlessness, abdominal pain, cough, fever, asthenia, rash and upper respiratory tract infection.
Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks (in case of status asthmaticus).
Patients with known aspirin sensitivity should continue avoidance of aspirin or other NSAID, while taking Montelukast.
In rare cases, patients on therapy with Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with churg-strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between Montelukast and these underlying conditions has not been established.
Montelukast is contraindicated to patients with hypersensitivity to any component of this product.
Use in Pregnancy & Lactation
Pregnancy: There are no adequate and well-controlled studies of Montelukast in pregnant women. Because animal reproductive studies are not always predictive of human response, so Montelukast should be used during pregnancy only if clearly needed.
Lactation: It is not known if Montelukast is excreted in human milk. Because many drugs are excreted in human milk, so caution should be exercised when Montelukast is given to a nursing mother.
Drug Interaction
Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no appropriate increase in adverse reactions.
Cytochrome P-450 inducers: Although Phenobarbital induces hepatic metabolism, no dosage adjustment for Montelukast is recommended. It is reasonable to employ appropriate clinical monitoring when potent cytochrome P-450 enzyme inducers, such as Phenobarbital or Rifampin, are co-administered with Montelukast.
There were no adverse experiences reported in the majority of overdosage reports. The most frequent adverse experiences observed were thirst, mydriasis, hyperkinesia, and abdominal pain. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.
Commercial Packaging
Montair 4 : Each box contains 3 Alu-Alu blister strip of 10 chewable tablets.
Montair 5 : Each box contains 3 Alu-Alu blister strip of 10 chewable tablets.
Montair 10 : Each box contains 3 Alu-Alu blister strip of 10 tablets.
Products from the same therapeutic group
Anti Asthmatics
Theophylline BP 300 mg & 400 mg sustained release tablet
Levosalbutamol Sulphate INN
Salbutamol Sulphate BP
Purisal Nebuliser Solution
Levosalbutamol Hydrochloride INN
Windel Plus
Salbutamol/Ipratropium Bromide
Ipratropium Bromide BP
Roflumilast 0.5 mg (500 mcg) Tablet
Budemet ConviCap
Budesonide and Formoterol Fumarate Dihydrate Convicap
Flutisal ConviCap
Fluticasone Propionate BP and Salmeterol Xinafoate BP inhalation powder.
Windel ConviCap
Salbutamol Sulphate BP inhalation powder.
Doxofylline INN Tablet
Leukotriene Receptor Antagonist
Montelukast Tablet
Steroidal Preparation
Cough Suppressant
Expectorant Syrup
Butamirate Citrate INN
Glycerol and Liquid Sugar 100 ml Syrup
Antitussive syrup
Dextromethorphan syrup
Drugs for Allergic Rhinitis
Nasal Steroidal Preparation
Momeson Nasal Spray
Mometasone Furoate BP
Budicort Nasal Spray
Budesonide BP
Lutisone Nasal Spray
Fluticasone Propionate BP
Fluticasone Furoate Nasal Spray
Antihistamine Preparation
Triamcinolone Acetonide BP Nasal Spray
Lopadine Nasal Spray
Olopatadine Hydrochloride INN
Mast Cell Stabiliser
Nasal Decongestant & Mast Cell Combination
Oxymetazoline Hydrochloride
Xylo Plus
Xylometazoline Hydrochloride BP and Sodium Cromoglicate BP
Mucolytic Expectorant
Ambroxol hydrochloride
Mucolytic Expectorant